Ranked above it
Care Bare Rx
Tells you exactly what you're buying — but $199 is a starting point, not a rate.
#1 on our tirzepatide provider ranking, above MEDVi at #132.
Read the Care Bare Rx review →
Provider review
MEDVi cost: $199/mo tirzepatide
A real price is published, but its own page states two figures for tirzepatide.
MEDVi's own tirzepatide landing page headlines "$166/mo — Price Locked" and separately states "$199 for Tirzepatide" in its body copy — a same-page contradiction we could not resolve from the page itself.
Verified August 2026
Reviewed by Marcus Webb
Transparency scorecard
1 of 4 disclosed openly
What MEDVi discloses about itself, read from its own pages — not estimated.
Pharmacy named & regulated
Not disclosed
Does not name a pharmacy or state a regulatory category anywhere on its own site.
State coverage published
Not disclosed
Publishes no state coverage list — availability is something you learn during signup.
A real price is published
Disclosed
A real dollar figure is published on its own site, not estimated.
No hidden commitment trap
Not disclosed
The advertised price requires a prepay, auto-refill, or other commitment we found and named.
This review's stake, stated plainly — some of the outbound links on this site are affiliate links; start a program through one and we may earn a commission at no extra cost to you. Straight about the rest, too: the write-ups say what each provider is actually worth, and a commission does not change a word of them. Full disclosure here.
On this page
What it actually costs
- Tirzepatide$199/mo
- Semaglutide$166/mo
What this price covers
Medication
Included
Provider visits
Not disclosed
Shipping
Not disclosed
Lab work
Not disclosed
Coaching
Not disclosed
The catch — The tirzepatide headline and body copy on the same page disagree about the price ($166 vs. $199) — not a prepay or auto-refill mechanism, but a same-page contradiction we could not resolve from MEDVi's own materials.
See plans at MEDViPrices read from MEDVi's own site · August 2026
What they advertise
MEDVi's own tirzepatide landing page headlines "$166/mo — Price Locked." The same page's body copy separately reads "$166 for Semaglutide or $199 for Tirzepatide."
What you actually pay
For semaglutide, the headline and body-copy figures agree: $166/month. For tirzepatide, the body copy states $199/month, distinct from the page's own $166 headline — we treat $199 as the stated tirzepatide figure since the body text names it specifically by drug, but the page's own inconsistency means this could not be confirmed as the actual billed amount.
The bottom line
MEDVi, LLC dba MEDVi is a telehealth marketing platform selling compounded tirzepatide and compounded semaglutide as headline, priced products, with compounded sermorelin available only as a post-checkout upsell. Its own site names three partner pharmacies (Triad Rx, RedRock Pharmacy, Beaker Pharmacy & Compounding) but states no 503A/503B regulatory category for any of them, and publishes no states-served list. FDA issued MEDVi, LLC a warning letter (MARCS-CMS 721455, February 20, 2026) over compounded-drug labeling — the same class of finding several peers here already carry with a knock, not a disqualifying one on its own. An earlier version of MEDVi's marketing was separately reported by outside journalism to have used fabricated physician names in ad creative; a check of MEDVi's current core site found no such named, invented physicians on its site today.
MEDVi appears on our tirzepatide provider ranking, our semaglutide provider ranking and our combined weight loss injections ranking. Nothing on this page is a performance claim.
Who it is for, and who it is not
A good fit if
- You want one company selling both compounded tirzepatide and compounded semaglutide, with a headline price for each published directly on its site.
- You're comfortable reading the FDA letter and the fabricated-marketing history yourself and deciding they don't change your view of the company today.
Look elsewhere if
- You want the number on the landing page to be the number you're billed — MEDVi's own tirzepatide page states two different prices for tirzepatide, and we could not determine from the page which one applies.
- A stated pharmacy regulatory category or a published states list is worth something to you — MEDVi discloses neither.
- An open FDA warning letter, or a documented history of fabricated marketing content, is a hard line for you regardless of what has since changed.
What MEDVi offers
Tap any compound to read our plain-English guide — what the evidence shows, how it is dosed, and what it costs elsewhere.
Who fills your prescription
No category stated
MEDVi does not name the pharmacy that fills your prescription.
What its own site says
Three named partner pharmacies appear in MEDVi's own site footer — Triad Rx, RedRock Pharmacy, and Beaker Pharmacy & Compounding — but neither "503A" nor "503B" appears anywhere on its site. Named pharmacies, no stated regulatory category.
What's the difference between 503A and 503B?
A 503A pharmacy compounds for one named patient; a 503B outsourcing facility manufactures in batches under CGMP. Neither is a quality guarantee on its own — a named facility is simply a fact you can check, and an unnamed “partner pharmacy network” is not. Compounded peptides are not FDA-approved.
Where you can get it
Not published
No states-served list or exclusion list was found.
The honest cons
The part they would rather you skipped
FDA issued MEDVi, LLC a warning letter (MARCS-CMS 721455, February 20, 2026, Center for Drug Evaluation and Research) — the same date, office, and "identifies '[name]' on the pictured label, suggesting [name] is the compounder when in fact it is not" template already documented here for a peer provider, addressed to MEDVi's own registered Delaware corporate address. Separately, outside investigative journalism (Futurism; Drug Discovery Trends) previously reported that MEDVi's advertising used fabricated physician names in ad creative; a check of MEDVi's current core site (2026-08-03) found no named, invented physicians anywhere on its site today, though this was not an exhaustive sweep of every historical ad. Neither finding disqualifies MEDVi on its own, but both are on the record here.
- MEDVi's own tirzepatide landing page states two different prices for tirzepatide on the same page ($166 headline vs. $199 body copy) — see this review's knock and pricing for the full finding.
- No 503A/503B regulatory category is stated for any of the three named partner pharmacies.
- No states-served list is published anywhere on the site.
- Compounded sermorelin is sold only as a post-checkout upsell, not as a standalone, independently priced product — it is not ranked for sermorelin for that reason.
None of this is unique to MEDVi — the whole category shares it.
How it compares
The providers we rank on our tirzepatide provider ranking — the most specific board MEDVi sits on — in the order that board ranks them. It sells into other categories too; see the boards listed above under the bottom line.
- Care Bare RxTells you exactly what you're buying — but $199 is a starting point, not a rate.
- SnagRx"Locked-In... for Life" pricing sits beside a countdown claiming otherwise.
- Breeze MedsNames the exact compound in its nav — then hides the price behind a quiz.
- Sprout HealthNames both pharmacies and a real 44-state list — but every price is a starting floor.
- TrimiNames its two pharmacies outright — then headlines a price that needs a year upfront.
- HealthRXStructured, disclosed pricing — but no legal entity is named anywhere on the site.
- SkinnyRxInjectable and oral tirzepatide — but the advertised price is a floor, not what you pay.
- Enhance MDHonest pricing and a real 503A claim — but it isn't in all 50 states, whatever it says.
149 more providers rank on our tirzepatide provider ranking — see the full ranking. Every provider we review →
Read this before you buy
A provider comparison is half the decision. The other half is whether the compound does anything for you at all. The evidence below is where that gets settled.
Ready to get started?
Prices and plans in this category change often — check MEDVi's current pricing before you decide. Ours was read from their own site in August 2026.
Facts on this page reflect MEDVi's own public disclosures when we last checked them, in August 2026. Prices and terms change without notice — confirm on MEDVi's site before you buy. Provider names and logos on this page identify the company under review; their use does not imply endorsement, sponsorship or affiliation. This page is informational and not medical advice; compounded peptides are not FDA-approved. See our disclosure and editorial policy.
MEDVi
2 compounds from $166/mo